Amber photobiomodulation versus tranexamic acid for the treatment of melasma: protocol for a double-blind, randomised controlled trial
Introduction Photobiomodulation (PBM) has been suggested as an alternative treatment for melasma. In vitro studies have shown PBM with amber light inhibits the tyrosinase enzyme, induces autophagy and reduces the melanin content, but randomised controlled clinical trials are still needed. This study...
Main Authors: | Christiane Pavani, Thais Rodrigues Galache, Marcelo Galache, Michelle Mota Sena |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-07-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/7/e073568.full |
Similar Items
-
Randomised, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma in an Australian cohort
by: Harini Rajgopal Bala, et al.
Published: (2022-01-01) -
Efficacy of Tranexamic Acid Mesotherapy Using a Novel Device versus Topical Tranexamic Acid in Patients with Melasma: Protocol for a Randomised Clinical Trial
by: Yash Kashikar, et al.
Published: (2024-02-01) -
Topical tranexamic acid as a promising treatment for melasma
by: Bahareh Ebrahimi, et al.
Published: (2014-01-01) -
Dermoscopic evaluation of tranexamic acid versus Vitamin C, with microneedling in the treatment of melasma: a comparative, split-face, single-blinded study
by: Asmaa Ibrahim Tahoun, et al.
Published: (2022-04-01) -
Effective drug delivery of intradermal tranexamic acid in the treatment of melasma
by: Nikita Muhutdinov, et al.
Published: (2023-04-01)